GRAIL, Inc. posted $36.2 million in revenue for Q3 2025, driven primarily by Galleri test sales. While losses narrowed compared to the prior year, the company still recorded a net loss of $89 million. Strong growth in test volumes and international expansion were key highlights.

GRAIL saw Q2 2025 revenue rise 11% year-over-year to $35.5M, driven by strong U.S. Galleri sales. The company narrowed its net loss compared to the prior year, but remained unprofitable due to high operating expenses and impairment charges.

Grail Inc delivered Q1 revenue of $31.8M, driven by Galleri test growth, while reporting a net loss of $106.2M. Adjusted EBITDA improved significantly year-over-year. The company maintains a strong cash position to support operations through 2028.

GRAIL reported a 26% increase in fourth-quarter revenue, reaching $38.3 million, with Galleri revenue growing 39% to $31.6 million. The company's net loss for the quarter was $97.1 million. GRAIL ended the year with a strong cash position of $767 million, extending its operational runway into 2028.

GRAIL reported a 38% increase in total revenue to $28.7 million, with Galleri revenue growing by 52% to $25.4 million. The company's net loss was $125.7 million, while adjusted EBITDA showed an improvement. Over 250,000 Galleri tests have been sold since launch, and the company is focusing on cost management and advancing registrational studies.

GRAIL reported a 43% year-over-year increase in revenue to $32.0 million for the second quarter of 2024. The company's strategic update includes reducing overall spend and focusing on core multi-cancer early detection priorities, which is expected to extend the cash runway into 2028.